Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
16 shown of 2,748 total abstracts
  1. Abstract 95732026-09-05 · 18:45 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-178
    G. Curigliano, S. Modi, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  2. Abstract 101362026-09-05 · 13:30 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    L. Paz-Ares, S. Antonia · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  3. Abstract 98252026-09-03 · 14:30 CT · S406
    Long-term follow-up of Keytruda adjuvant for metastatic melanoma: KEYNOTE-446
    F. Andre, T. Mok, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  4. Abstract 104972026-09-04 · 14:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-914
    T. Mok, S. Antonia · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  5. Abstract 104052026-09-04 · 19:30 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    N. Rizvi, J. Cortes, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  6. Abstract 101062026-09-03 · 16:00 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Modi, L. Paz-Ares, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  7. Abstract 104742026-09-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-24 study)
    M. Krop, G. Curigliano, S. Antonia, et al. · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  8. Abstract 100432026-09-03 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    S. Antonia, F. Andre, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  9. Abstract 98092026-09-05 · 14:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-721 study)
    M. Reck, T. Mok, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  10. Abstract 100942026-09-05 · 19:00 CT · S406
    CheckMate-941: Opdivo (nivolumab) 3L+ in metastatic melanoma
    S. Peters, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  11. Abstract 101572026-09-05 · 15:00 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-537 study)
    G. Curigliano, S. Modi, M. Reck · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  12. Abstract 104732026-09-02 · 14:45 CT · Hall B1
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-880
    S. Peters, T. Mok, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  13. Abstract 102032026-09-04 · 19:45 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-410
    M. Krop, M.C. Garassino, A. Spira · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  14. Abstract 96332026-09-05 · 15:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-519 study)
    M. Krop, A. Spira, S. Modi, et al. · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  15. Abstract 97892026-09-04 · 18:45 CT · Arie Crown Theater
    CheckMate-888: Opdivo (nivolumab) maintenance in metastatic melanoma
    M.C. Garassino, H. Rugo, P. Schmid · Royal Marsden Hospital
    Poster Discussion SessionMelanoma📄🖼️
  16. Abstract 98052026-09-04 · 13:45 CT · E450
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-908
    M.C. Garassino, C. Saura, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.